UCB SA (OTCMKTS:UCBJY) Short Interest Down 60.4% in July

UCB SA (OTCMKTS:UCBJY) was the target of a significant drop in short interest in the month of July. As of July 15th, there was short interest totaling 2,283 shares, a drop of 60.4% from the June 30th total of 5,769 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 58,706 shares, the days-to-cover ratio is currently 0.0 days.

UCB Stock Performance

OTCMKTS UCBJY opened at $139.57 on Tuesday. UCB has a twelve month low of $103.43 and a twelve month high of $168.76. The company has a quick ratio of 1.04, a current ratio of 1.38 and a debt-to-equity ratio of 0.20. The business has a 50-day moving average price of $143.86 and a 200-day moving average price of $147.79.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on UCBJY. Zacks Research upgraded shares of UCB from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Barclays lowered UCB from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 15th. Finally, Jefferies Financial Group raised UCB to a “moderate sell” rating in a report on Monday, June 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold”.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.